Zhichen Xu | Radiation Oncology | Best Researcher Award

Zhichen Xu | Radiation Oncology | Best Researcher Award

First Hospital of Quanzhou | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. ZHICHEN XU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Xu Zhichen, originally from Putian and a member of the Han ethnic group, embarked on his medical journey at Luzhou Medical College, where he earned his Bachelor’s degree in Clinical Neurology (2005–2010). Driven by a growing interest in cancer care, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013). His postgraduate training, conducted at the Fujian Provincial Tumor Hospital, laid the foundation for his specialization in radiotherapy.

🩺PROFESSIONAL ENDEAVORS

After completing his academic training, Mr. Xu underwent standardized residency training at Quanzhou First Hospital (2013.9–2014.9). Since September 2014, he has been an integral part of the hospital’s Radiotherapy Department, where he applies advanced radiotherapeutic techniques in clinical oncology. In 2024, he achieved the Vice Senior Certification in Radiotherapy, a testament to his professional growth and clinical mastery over the past decade.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON RADIATION ONCOLOGY

Mr. Xu specializes in Radiation Oncology, with a particular emphasis on esophageal cancer, focusing on enhancing therapeutic efficacy and patient outcomes. His clinical efforts are complemented by a strong commitment to research in radiotherapy optimization, side effect mitigation, and individualized treatment approaches.

🌍IMPACT AND INFLUENCE

A rising leader in regional cancer care, Mr. Xu is a core member of the Youth Committee of the Fujian Radiation Oncology Society. His selection for the “Hundred Talent Program” at Quanzhou First Hospital underlines his value as a future-forward clinician contributing to institutional development and innovation in cancer treatment.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Mr. Xu Zhichen aims to deepen his impact through work on precision radiotherapy, multidisciplinary cancer management, and the integration of AI and imaging technologies in clinical decision-making. He is committed to mentoring young oncologists and fostering collaborative research within and beyond Quanzhou.

🧬CONCLUSION

Mr. Xu Zhichen exemplifies the ideal blend of clinical expertise, research acumen, and leadership potential in the field of Radiation Oncology. With a focus on esophageal cancer, he continues to shape the future of radiotherapy in Fujian Province while contributing meaningfully to national and international cancer care standards.

 

📊🔬NOTABLE PUBLICATION:

A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma

Authors: Xu Zhichen, Su Baoan, Lin Mingqiang, Xu Qinghua, Qu Mengke
Journal: Scientific Reports
Year: 2025

Prof. Linghua Li | Cancer Science | Best Researcher Award

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

📊🔬NOTABLE PUBLICATION:
  • Utilizing Protein–Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023